Phaseline

Targets › STEAP1

STEAP1 (STEAP1 protein): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Does not function as a metalloreductase due to the absence of binding sites for the electron-donating substrate NADPH. Promotes Fe(3+) reduction when fused to the NADPH-binding domain of STEAP4. (UniProt, Q9UHE8)

Open in Phaseline: the race on STEAP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Adcentrx TherapeuticsADRX-0405
Anti-STEAP1 antibody-drug conjugate
STEAP1Phase 1Solid TumorsDec 2026
Fred Hutchinson Cancer CenterAnti-STEAP1 CAR T-cells
Anti-STEAP1 chimeric antigen receptor T-cell therapy
STEAP1Phase 1Metastatic Castration-Resistant Prostate CarcinomaMar 2027

Conditions

Solid Tumors (1) Metastatic Castration-Resistant Prostate Carcinoma (1)

Modalities

small molecule (1), mixed (1)

Companies

Adcentrx Therapeutics (1) Fred Hutchinson Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.